SCHEMBL24253296

SCHEMBL24253296

CC(C)Cc1cc(Cl)c2c(n1)CN(C)CC2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34
ADRA2A P08913 3/20 0.33
ADRA2B P18089 3/20 0.33
ADRA2C P18825 3/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1A P35348 3/20 0.33
ADRA1B P35368 3/20 0.33
CYP2C19 P33261 2/20 0.33
CYP2D6 P10635 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
PDE5A O76074 1/20 0.31
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22993414 0.76 ALDH1A1 (0.39) GAAALDH1A1HPGDLMNATP53
SCHEMBL24253486 0.72 MAOA (0.40) CYP2C19DRD2DRD1DRD5
SCHEMBL22993267 0.70 CYP2C19 (0.43) GAAALDH1A1HPGDHTTCYP2C19
SCHEMBL24253492 0.69 KLKB1 (0.33) GAAALDH1A1HPGDLMNATP53
SCHEMBL22993375 0.68 CYP2C19 (0.44) GAAALDH1A1HPGDHTTCYP2C19
SCHEMBL29110072 0.68 KDM4E (0.42) GAAALDH1A1HPGDNPSR1KDM4E
SCHEMBL30685094 0.68 KDM4E (0.42) GAAALDH1A1HPGDNPSR1KDM4E
SCHEMBL22993455 0.66 CYP2C19 (0.32) GAAALDH1A1HPGDLMNACYP2C19
SCHEMBL12134807 0.64 ALDH1A1 (0.49) GAAALDH1A1HPGDLMNATP53
SCHEMBL23198626 0.63 CHRM4 (0.41) GAAALDH1A1HPGDLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GAA 151/4885ALDH1A1 1622/4885HPGD 506/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 GAA 151/4885ALDH1A1 1622/4885HPGD 506/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 GAA 151/4885ALDH1A1 1622/4885HPGD 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.